GenFleet Therapeutics
Industry
- Pharmaceuticals
- Biotechnology
Latest on GenFleet Therapeutics
Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included
The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including risi
Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and
Amid the global race to scour for the best partners and approaches for KRAS G12C inhibitors for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the hard-to-drug mutat